Eagle Financial Statements From 2010 to 2024
EGRX Stock | USD 4.55 0.22 4.61% |
Gross Profit 221.7 M | Profit Margin 0.0464 | Market Capitalization 61.8 M | Enterprise Value Revenue 0.4494 | Revenue 257.6 M |
Eagle Pharmaceuticals Total Revenue |
|
Check Eagle Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eagle main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 M, Interest Expense of 4.9 M or Selling General Administrative of 118.5 M, as well as many exotic indicators such as Price To Sales Ratio of 1.3, Ptb Ratio of 1.77 or Days Sales Outstanding of 129. Eagle financial statements analysis is a perfect complement when working with Eagle Pharmaceuticals Valuation or Volatility modules.
Eagle | Select Account or Indicator |
Eagle Pharmaceuticals Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Pharmaceuticals Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Pharmaceuticals Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Pharmaceuticals Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Eagle Fundamental Market Drivers
Forward Price Earnings | 11.3379 | |
Cash And Short Term Investments | 55.3 M |
Eagle Upcoming Events
11th of March 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
30th of September 2023 Last Quarter Report | View |
About Eagle Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Eagle Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Eagle Pharmaceuticals investors use historical funamental indicators, such as Eagle Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Eagle Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Eagle Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eagle Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eagle Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eagle Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Current Deferred Revenue | 29.2 M | 17.3 M | |
Total Revenue | 364.1 M | 382.3 M | |
Cost Of Revenue | 109.2 M | 114.6 M | |
Stock Based Compensation To Revenue | 0.05 | 0.06 | |
Sales General And Administrative To Revenue | 0.28 | 0.29 | |
Research And Ddevelopement To Revenue | 0.11 | 0.12 | |
Capex To Revenue | (0.0005) | (0.0005) | |
Revenue Per Share | 22.03 | 23.13 | |
Ebit Per Revenue | 0.15 | 0.16 |
Pair Trading with Eagle Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eagle Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eagle Stock
0.73 | ACB | Aurora Cannabis Trending | PairCorr |
0.7 | CGC | Canopy Growth Corp Trending | PairCorr |
0.5 | ELYM | Eliem Therapeutics | PairCorr |
0.49 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Eagle Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eagle Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eagle Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eagle Pharmaceuticals to buy it.
The correlation of Eagle Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eagle Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eagle Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eagle Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Eagle Pharmaceuticals Correlation against competitors. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Eagle Stock analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share 0.85 | Revenue Per Share 19.684 | Quarterly Revenue Growth (0.13) | Return On Assets 0.0663 |
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.